EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers

Hideaki Yamakawa, Kenji Kusano, Rie Kawabe, Shintaro Sato, Hiroki Ohta, Moe Nomaki, Tomohiro Oba, Chisa Uzuka, Keiichi Akasaka, Masako Amano, Hidekazu Matsushima, Jun Araya

Cancer Treatment and Research Communications · 2026

DOI: 10.1016/j.ctarc.2026.101142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Hideaki Yamakawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan; Department of Respiratory Medicine…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, B7-H1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors (ICIs) are effective in advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50 %; however, responses remain heterogeneous. We investigated the predictive value of nutritional and inflammatory indices (Prognostic Nutritional Index [PNI], Geriatric Nutritional Risk Index [GNRI], and neutrophil-to-lymphocyte ratio [NLR]), for durable clinical benefit (DCB) and progression-free survival (PFS) in this population. METHODS: We retrospectively analyzed 125 patients (ECOG PS 0-2) with advanced NSCLC and PD-L1 ≥50 % treated with pembrolizumab. A composite score (0-3) was defined by PNI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedB7-H1 AntigenHumansFemaleMaleAgedRetrospective StudiesMiddle AgedProgression-Free SurvivalAged, 80 and overInflammationPrognosisNutritional Status

Stichwörter der Autor:innen

Durable clinical benefitImmune checkpoint inhibitorsImmune-nutritional statusInterstitial lung diseaseNon–small cell lung cancer

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan; Department of Respiratory Medicine, Tokyo Jikei University Hospital, 3-25-8 Nishi-shinbashi, Minato-ku,…
  • Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan.
  • Department of Respiratory Medicine, Tokyo Jikei University Hospital, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.

Zitieren

APA

Yamakawa, H., Kusano, K., Kawabe, R., Sato, S., Ohta, H., Nomaki, M., Oba, T., Uzuka, C., Akasaka, K., Amano, M., Matsushima, H., & Araya, J. (2026). Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101142

Vancouver

Yamakawa H, Kusano K, Kawabe R, Sato S, Ohta H, Nomaki M, et al. Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101142

BibTeX
@article{Yamakawa2026,
  author = {Yamakawa, Hideaki and Kusano, Kenji and Kawabe, Rie and Sato, Shintaro and Ohta, Hiroki and Nomaki, Moe and Oba, Tomohiro and Uzuka, Chisa and Akasaka, Keiichi and Amano, Masako and Matsushima, Hidekazu and Araya, Jun},
  title = {Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  doi = {10.1016/j.ctarc.2026.101142}
}
Kostenlos starten →